Biogen BIIB RITUXAN — Until Second GAZYVA Threshold Date

Similar metrics at other companies

LGNDRylaze — Total revenues and income

$3.22M+3.3%

JAZZRylaze/Enrylaze — Revenue from Contract with Customer, Excluding Assessed Tax

$103.7M+10.1%

PCRXZILRETTA — Total net product sales

$26.77M+14.7%

LGNDRylaze — Total revenue and income

$3.22M+3.3%

JNJRYBREVANT + LAZCLUZE — Sales to customers (Note 9)

$257M+82.3%

OGNRosuzet — Revenue

$6M+50.0%

Questions, answered.

What is Biogen's RITUXAN — until second GAZYVA threshold date?

Biogen (BIIB) reported RITUXAN — until second GAZYVA threshold date of 37.5% in Q1 2026.

How has Biogen's RITUXAN — until second GAZYVA threshold date changed year-over-year?

Biogen's RITUXAN — until second GAZYVA threshold date decreased by 0.0% year-over-year, from 37.5% to 37.5%.

What is the long-term trend for Biogen's RITUXAN — until second GAZYVA threshold date?

Over 2 years (2023 to 2025), Biogen's RITUXAN — until second GAZYVA threshold date has grown at a 0.0% compound annual growth rate (CAGR), from 150% to 150%.

What does RITUXAN — until second GAZYVA threshold date mean?

This metric tracks the operational or financial status of a product collaboration during the period preceding a specific milestone related to a secondary product's regulatory or market performance. It serves as a temporal marker for when the current profit-sharing arrangement remains in effect. Investors use this to determine the duration of existing economic terms before a contractual shift occurs.